On Nov. 10, 2020, Altimmune announced an agreement with Lonza for the manufacturing of AdCOVIDﾙ, Altimmuneﾒs next-generation, single-dose intranasal vaccine candidate for COVID-19. AdCOVID is a single-dose COVID-19 vaccine candidate that has the potential to be conveniently administered via an intranasal spray.